Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$121.70 USD

121.70
1,317,401

-3.44 (-2.75%)

Updated Jul 17, 2024 01:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Stock Market News for Feb 15, 2022

by Zacks Equity Research

Wall Street lower on Monday as geopolitical tensions between Russia and Ukraine intensified.

Will Patient Days Drive Community Health (CYH) Q4 Earnings?

by Zacks Equity Research

Community Health Systems' (CYH) fourth-quarter results are likely to reflect a higher occupancy rate and average length of stay.

Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission

by Zacks Equity Research

Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $161.32, marking a +0.56% move from the previous day.

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids

by Zacks Equity Research

Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.

Ekta Bagri headshot

4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates

by Ekta Bagri

Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.

Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $169.61, moving -1.81% from the previous trading session.

Is a Beat Likely for Amgen (AMGN) This Earnings Season?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More

by Zacks Equity Research

Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.

Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod

by Zacks Equity Research

The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.

Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab

by Zacks Equity Research

After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.

Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel

by Zacks Equity Research

Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.

Is a Beat Likely for Biogen (BIIB) This Earnings Season?

by Zacks Equity Research

Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.

Earnings Data to Flood Wall Street This Week

by Zacks Equity Research

Earnings Data to Flood Wall Street This Week.

Mark Vickery headshot

Good Riddance to a Rough Trading Month

by Mark Vickery

It would be easy to forget we started out its first few trading days notching new all-time highs on both the Dow and the S&P 500.

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and J&J

by Zacks Equity Research

Pfizer, BioNTech, Moderna and J&J are included in this analyst blog.

Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.

Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab

by Zacks Equity Research

Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More

by Zacks Equity Research

Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.

Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?

by Zacks Equity Research

Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $157.30 in the latest trading session, marking a -1.73% move from the prior day.

4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

by Zacks Equity Research

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.

Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant

by Zacks Equity Research

Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.